P388 leukemia in CDF₁ mice as the test system for studies of tumor-associated neoangiogenesis and hypercoagulation

A P Trashkov; A V Panchenko; E S Kayukova; R V Korablev; V A Pechatnikova; A G Vasil'ev; V N Anisimov

doi:10.1007/s10517-015-2793-0

P388 leukemia in CDF₁ mice as the test system for studies of tumor-associated neoangiogenesis and hypercoagulation

Bull Exp Biol Med. 2015 Feb;158(4):497-9. doi: 10.1007/s10517-015-2793-0. Epub 2015 Feb 24.

Authors

A P Trashkov¹, A V Panchenko, E S Kayukova, R V Korablev, V A Pechatnikova, A G Vasil'ev, V N Anisimov

Affiliation

¹ St. Petersburg State Pediatric Medical University, the Ministry of Health of the Russian Federation, St. Petersburg, Russia, alexandr.trashkov@gmail.com.

PMID: 25708334
DOI: 10.1007/s10517-015-2793-0

Abstract

Blood levels of vascular endothelial growth factor, the main marker of angiogenesis activity, and coagulation hemostasis were studied in CDF1 mice with transplanted P-388 lymphocytic leukemia. Blood levels of vascular endothelial growth factor increased by 168% in mice with tumors. The animals developed the hypercoagulation syndrome manifesting in shorter activated partial thromboplastin time and prothrombin time and development of hyperfibrinogenemia.

MeSH terms

Animals
Blood Coagulation Disorders / physiopathology*
Enzyme-Linked Immunosorbent Assay
Leukemia P388 / physiopathology*
Male
Mice
Neoplasm Transplantation / physiology
Neovascularization, Pathologic / blood
Neovascularization, Pathologic / physiopathology*
Partial Thromboplastin Time
Prothrombin Time
Statistics, Nonparametric
Vascular Endothelial Growth Factor A / blood*

Substances

Vascular Endothelial Growth Factor A